Cargando…
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
BACKGROUND: Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs. METHODS: This prospective, open-label observational study enrolle...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931564/ https://www.ncbi.nlm.nih.gov/pubmed/36792812 http://dx.doi.org/10.1007/s40120-023-00448-x |
_version_ | 1784889273943588864 |
---|---|
author | Jaber, Aliya Patel, Meera Sylvester, Andrew Yarussi, Mary Kalina, J. Tamar Mendoza, Jason P. Avila, Robin L. Tremblay, Matthew A. |
author_facet | Jaber, Aliya Patel, Meera Sylvester, Andrew Yarussi, Mary Kalina, J. Tamar Mendoza, Jason P. Avila, Robin L. Tremblay, Matthew A. |
author_sort | Jaber, Aliya |
collection | PubMed |
description | BACKGROUND: Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs. METHODS: This prospective, open-label observational study enrolled 45 participants treated with natalizumab (n = 12), ocrelizumab (n = 16), fumarates (dimethyl fumarate or diroximel fumarate, n = 11), or interferon beta (n = 6); ages 18–65 years inclusive; stable on DMT for at least 6 months. Responder rates, anti-SARS-CoV-2 spike receptor-binding domain IgG (anti-RBD) geometric mean titers (GMTs), antigen-specific T cells, and vaccination-related adverse events were evaluated at baseline and 8, 24, 36, and 48 weeks after first mRNA-1273 (Moderna) dose. RESULTS: At 8 weeks post vaccination, all natalizumab-, fumarate-, and interferon beta-treated participants generated detectable anti-RBD IgG titers, compared to only 25% of the ocrelizumab cohort. At 24 and 36 weeks post vaccination, natalizumab-, fumarate-, and interferon beta-treated participants continued to demonstrate detectable anti-RBD IgG titers, whereas participants receiving ocrelizumab did not. Anti-RBD GMTs decreased 81.5% between 8 and 24 weeks post vaccination for the non-ocrelizumab-treated participants, with no significant difference between groups. At 36 weeks post vaccination, ocrelizumab-treated participants had higher proportions of spike-specific T cells compared to other treatment groups. Vaccine-associated side effects were highest in the ocrelizumab arm for most symptoms. CONCLUSIONS: These results suggest that humoral response to mRNA-1273 COVID-19 vaccine is preserved and similar in PwMS treated with natalizumab, fumarate, and interferon beta, but muted with ocrelizumab. All DMTs had preserved T cell response, including the ocrelizumab cohort, which also had a greater risk of vaccine-related side effects. |
format | Online Article Text |
id | pubmed-9931564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-99315642023-02-16 COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy Jaber, Aliya Patel, Meera Sylvester, Andrew Yarussi, Mary Kalina, J. Tamar Mendoza, Jason P. Avila, Robin L. Tremblay, Matthew A. Neurol Ther Brief Report BACKGROUND: Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs. METHODS: This prospective, open-label observational study enrolled 45 participants treated with natalizumab (n = 12), ocrelizumab (n = 16), fumarates (dimethyl fumarate or diroximel fumarate, n = 11), or interferon beta (n = 6); ages 18–65 years inclusive; stable on DMT for at least 6 months. Responder rates, anti-SARS-CoV-2 spike receptor-binding domain IgG (anti-RBD) geometric mean titers (GMTs), antigen-specific T cells, and vaccination-related adverse events were evaluated at baseline and 8, 24, 36, and 48 weeks after first mRNA-1273 (Moderna) dose. RESULTS: At 8 weeks post vaccination, all natalizumab-, fumarate-, and interferon beta-treated participants generated detectable anti-RBD IgG titers, compared to only 25% of the ocrelizumab cohort. At 24 and 36 weeks post vaccination, natalizumab-, fumarate-, and interferon beta-treated participants continued to demonstrate detectable anti-RBD IgG titers, whereas participants receiving ocrelizumab did not. Anti-RBD GMTs decreased 81.5% between 8 and 24 weeks post vaccination for the non-ocrelizumab-treated participants, with no significant difference between groups. At 36 weeks post vaccination, ocrelizumab-treated participants had higher proportions of spike-specific T cells compared to other treatment groups. Vaccine-associated side effects were highest in the ocrelizumab arm for most symptoms. CONCLUSIONS: These results suggest that humoral response to mRNA-1273 COVID-19 vaccine is preserved and similar in PwMS treated with natalizumab, fumarate, and interferon beta, but muted with ocrelizumab. All DMTs had preserved T cell response, including the ocrelizumab cohort, which also had a greater risk of vaccine-related side effects. Springer Healthcare 2023-02-16 /pmc/articles/PMC9931564/ /pubmed/36792812 http://dx.doi.org/10.1007/s40120-023-00448-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Brief Report Jaber, Aliya Patel, Meera Sylvester, Andrew Yarussi, Mary Kalina, J. Tamar Mendoza, Jason P. Avila, Robin L. Tremblay, Matthew A. COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy |
title | COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy |
title_full | COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy |
title_fullStr | COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy |
title_full_unstemmed | COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy |
title_short | COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy |
title_sort | covid-19 vaccine response in people with multiple sclerosis treated with dimethyl fumarate, diroximel fumarate, natalizumab, ocrelizumab, or interferon beta therapy |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931564/ https://www.ncbi.nlm.nih.gov/pubmed/36792812 http://dx.doi.org/10.1007/s40120-023-00448-x |
work_keys_str_mv | AT jaberaliya covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy AT patelmeera covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy AT sylvesterandrew covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy AT yarussimary covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy AT kalinajtamar covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy AT mendozajasonp covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy AT avilarobinl covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy AT tremblaymatthewa covid19vaccineresponseinpeoplewithmultiplesclerosistreatedwithdimethylfumaratediroximelfumaratenatalizumabocrelizumaborinterferonbetatherapy |